FDA approves daratumumab plus VMP for transplant ineligible myeloma patients

/0 Comments/in , /by

 

On 7 May 2018 the US FDA approved daratumumab (DARZALEX®) in combination with the VMP regimen (bortezomib (VELCADE®), melphalan, and prednisone) for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).

You might also like
ASCO-2019-lung-cancer-NSCLC-ASCO19-SCLC-mesothelioma-KEYNOTE-189-KEYNOTE-001-IMpower150-MYSTIC-LCMC3-Lung-MAP-S1400G-S1400I-Flaura-CALGB-30901-DETERRED-COMPASS-FDA approves apalutamide for non-metastatic castration-resistant prostate cancer
the-evolving-role-of-nk1-in-cinv-management-chemotherapy-induced-nausea-vomiting-akynzeo-nepa-palonosetron-netupitant-1The evolving role of NK1 in CINV management
ASCO-2019-lung-cancer-NSCLC-ASCO19-SCLC-mesothelioma-KEYNOTE-189-KEYNOTE-001-IMpower150-MYSTIC-LCMC3-Lung-MAP-S1400G-S1400I-Flaura-CALGB-30901-DETERRED-COMPASS-Erdafitinib FDA approved for the treatment of metastatic urothelial carcinoma
ASCO-2019-lung-cancer-NSCLC-ASCO19-SCLC-mesothelioma-KEYNOTE-189-KEYNOTE-001-IMpower150-MYSTIC-LCMC3-Lung-MAP-S1400G-S1400I-Flaura-CALGB-30901-DETERRED-COMPASS-FDA approved abiraterone acetate tablets plus prednisone for metastatic high-risk CSPC
One-year-data-of-bimekizumab-versus-ustekinumab-for-plaque-psoriasis-in-the-BE-VIVID-trialOne-year data of bimekizumab versus ustekinumab for plaque psoriasis in the BE VIVID trial
US and Chinese Studies Suggest More Severe Outcomes in COVID-19 Patients with CancerMore Severe Outcomes in COVID-19 Patients with Cancer
ASCO-2019-lung-cancer-NSCLC-ASCO19-SCLC-mesothelioma-KEYNOTE-189-KEYNOTE-001-IMpower150-MYSTIC-LCMC3-Lung-MAP-S1400G-S1400I-Flaura-CALGB-30901-DETERRED-COMPASS-ASCO 2019 Lung Cancer: 36 Oral Presentations of the ASCO19 lung cancer track summarised
0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *

FDA approves dabrafenib plus trametinib for anaplastic thyroid cancer with BRAF...AACR 2018: first-line atezolizumab, bevacizumab plus chemotherapy active in...